A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease
Open Access
- 7 December 1995
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 333 (23), 1528-1534
- https://doi.org/10.1056/nejm199512073332303
Abstract
Reverse-transcriptase inhibitors have only moderate clinical efficacy against the human immunodeficiency virus type 1 (HIV-1). Ritonavir is an inhibitor of HIV-1 protease with potent in vitro anti-HIV properties and good oral bioavailability.This publication has 15 references indexed in Scilit:
- Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitorAntimicrobial Agents and Chemotherapy, 1995
- Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC)The Journal of Infectious Diseases, 1995
- Rapid and Precise Quantification of HIV-1 RNA in Plasma Using a Branched DNA Signal Amplification AssayJAIDS Journal of Acquired Immune Deficiency Syndromes, 1995
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral TherapyAnnals of Internal Medicine, 1995
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Quantitation of Human Immunodeficiency Virus by Culture and Polymerase Chain Reaction in Response to Didanosine after Long-Term Therapy with ZidovudineThe Journal of Infectious Diseases, 1994
- Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agentsAntimicrobial Agents and Chemotherapy, 1993
- The HIV-1 Protease as a Therapeutic Target for AIDSAIDS Research and Human Retroviruses, 1992